BEAM
Price
$26.97
Change
-$0.92 (-3.30%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
2.83B
27 days until earnings call
Intraday BUY SELL Signals
GLPG
Price
$34.79
Change
+$0.19 (+0.55%)
Updated
Feb 4, 02:40 PM (EDT)
Capitalization
2.25B
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs GLPG

Header iconBEAM vs GLPG Comparison
Open Charts BEAM vs GLPGBanner chart's image
Beam Therapeutics
Price$26.97
Change-$0.92 (-3.30%)
Volume$10.5K
Capitalization2.83B
Galapagos
Price$34.79
Change+$0.19 (+0.55%)
Volume$530
Capitalization2.25B
BEAM vs GLPG Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. GLPG commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and GLPG is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (BEAM: $27.89 vs. GLPG: $34.60)
Brand notoriety: BEAM and GLPG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 66% vs. GLPG: 152%
Market capitalization -- BEAM: $2.83B vs. GLPG: $2.25B
BEAM [@Biotechnology] is valued at $2.83B. GLPG’s [@Biotechnology] market capitalization is $2.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileGLPG’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • GLPG’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than GLPG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while GLPG’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 6 bearish.
  • GLPG’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GLPG is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -9.15% price change this week, while GLPG (@Biotechnology) price change was -0.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

GLPG is expected to report earnings on Feb 24, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.83B) has a higher market cap than GLPG($2.25B). GLPG YTD gains are higher at: 5.810 vs. BEAM (0.613). GLPG has higher annual earnings (EBITDA): -133.96M vs. BEAM (-434.55M). GLPG has more cash in the bank: 3.05B vs. BEAM (1.08B). GLPG has less debt than BEAM: GLPG (7.5M) vs BEAM (151M). GLPG has higher revenues than BEAM: GLPG (287M) vs BEAM (55.7M).
BEAMGLPGBEAM / GLPG
Capitalization2.83B2.25B126%
EBITDA-434.55M-133.96M324%
Gain YTD0.6135.81011%
P/E RatioN/A53.70-
Revenue55.7M287M19%
Total Cash1.08B3.05B35%
Total Debt151M7.5M2,013%
FUNDAMENTALS RATINGS
BEAM vs GLPG: Fundamental Ratings
BEAM
GLPG
OUTLOOK RATING
1..100
7413
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
4447
P/E GROWTH RATING
1..100
10059
SEASONALITY SCORE
1..100
507

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (35) in the null industry is somewhat better than the same rating for GLPG (82) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than GLPG’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as GLPG (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to GLPG’s over the last 12 months.

GLPG's SMR Rating (95) in the Biotechnology industry is in the same range as BEAM (97) in the null industry. This means that GLPG’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's Price Growth Rating (44) in the null industry is in the same range as GLPG (47) in the Biotechnology industry. This means that BEAM’s stock grew similarly to GLPG’s over the last 12 months.

GLPG's P/E Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that GLPG’s stock grew somewhat faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMGLPG
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
69%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
57%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
Bullish Trend 2 days ago
64%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 16 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
GLPG
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EIFVX22.110.20
+0.91%
Eaton Vance Focused Value Opps I
TEQIX16.460.13
+0.80%
Franklin Mutual Quest A
BRSYX15.670.02
+0.13%
MFS Blended Research Small Cap Eq R6
GGOTX13.42-0.02
-0.15%
Goldman Sachs Mid Cap Growth Inv
FRGSX106.81-1.62
-1.49%
Franklin Growth C

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-0.11%
CRSP - BEAM
66%
Closely correlated
+1.34%
RXRX - BEAM
62%
Loosely correlated
-1.91%
NTLA - BEAM
62%
Loosely correlated
-0.08%
PRME - BEAM
61%
Loosely correlated
+0.26%
VIR - BEAM
58%
Loosely correlated
-0.39%
More

GLPG and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLPG has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if GLPG jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLPG
1D Price
Change %
GLPG100%
+1.08%
VCYT - GLPG
43%
Loosely correlated
-1.10%
BEAM - GLPG
38%
Loosely correlated
-0.11%
AXON - GLPG
35%
Loosely correlated
-1.89%
NEUP - GLPG
35%
Loosely correlated
-0.37%
DYN - GLPG
34%
Loosely correlated
+1.07%
More